Smoking cessation in emergency departments: a reality check
Abstract
Emergency Departments (EDs) see a high prevalence of people who smoke, many of whom present with acute smoking-related conditions (e.g., myocardial infarction, stroke, pneumonia, and asthma/COPD exacerbations). The immediacy of illness creates a strong "teachable moment," increasing receptiveness to risk communication and behavior change. Evidence indicates that pairing brief counseling with point-of-care therapeutic support and structured follow-up improves abstinence, although effects vary with local infrastructure, product availability, and staffing models. Despite this promise, scale-up is often constrained by economic barriers, limited staffing and training, and weak integration of cessation workflows into routine ED practice. The aim of this article is to provide a reality check on ED-based smoking cessation by synthesizing evidence on effectiveness, feasibility, cost-effectiveness, and safety across health-system contexts, and by outlining pragmatic delivery models and research priorities. Embedding low-friction, clinically governed cessation bundles within EDs has the potential to convert acute presentations into durable quit attempts and reduce smoking-related harm at scale, though this population-level impact remains a hypothesis to be tested. Future work should prioritize pragmatic and implementation trials with biochemically verified outcomes, integration metrics, equity impacts, and cost-utility analyses to guide sustainable adoption across diverse settings.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.